We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-0.12%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
+$128M
(+7.8%)
Cap. Flow
+$150M
Cap. Flow
% of AUM
8.47%
Top 10 Holdings %
Top 10 Hldgs %
57.1%
Holding
53
New
17
Increased
12
Reduced
9
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$151M |
| 2 |
Intuitive Surgical
ISRG
|
+$116M |
| 3 |
AET
Aetna Inc
AET
|
+$100M |
| 4 |
Quest Diagnostics
DGX
|
+$83.3M |
| 5 |
Danaher
DHR
|
+$78.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$117M |
| 2 |
Edwards Lifesciences
EW
|
+$109M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$77.1M |
| 4 |
Cigna
CI
|
+$74.6M |
| 5 |
Eli Lilly
LLY
|
+$66.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.84% |
| 2 | Financials | 5.88% |
| 3 | Consumer Staples | 3.88% |
| 4 | Materials | 0.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $174M | 9.81% |
1,500,000
+1,356,150
| +943% | +$151M |
|
2
Labcorp
LH
$25.9B
| $148M | 8.34% |
1,338,600
+465,600
| +53% | +$51.7M |
|
|
3
Intuitive Surgical
ISRG
$126B
| $111M | 6.27% |
+1,575,000
| New | +$116M |
|
|
AET
4
DELISTED
Aetna Inc
AET
| $104M | 5.88% |
+839,030
| New | +$100M |
|
|
5
Quest Diagnostics
DGX
$25.9B
| $103M | 5.84% |
1,125,000
+966,220
| +609% | +$83.3M |
|
|
QGENF
6
DELISTED
QIAGEN NV
QGENF
| $79.9M | 4.51% |
2,850,000
+575,000
| +25% | +$16.1M |
|
|
7
Danaher
DHR
$138B
| $78.2M | 4.42% |
+1,133,245
| New | +$78.7M |
|
8
Incyte
INCY
$24.9B
| $74.3M | 4.2% |
741,360
+141,360
| +24% | +$13.8M |
|
9
Zimmer Biomet
ZBH
$18.4B
| $69.6M | 3.94% |
695,003
-386,497
| -36% | -$41.4M |
|
|
WOOF
10
DELISTED
VCA Inc.
WOOF
| $68.7M | 3.88% |
+1,000,000
| New | +$65.3M |
|
11
UnitedHealth
UNH
$383B
| $65.2M | 3.69% |
+407,580
| New | +$60.9M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.7B
| $64.2M | 3.63% |
+775,000
| New | +$66.6M |
|
|
SYNH
13
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $59.1M | 3.34% |
1,123,920
+123,920
| +12% | +$6M |
|
|
14
Cigna
CI
$76.1B
| $57.4M | 3.24% |
430,140
-569,860
| -57% | -$74.6M |
|
15
Pacira BioSciences
PCRX
$1.06B
| $50.9M | 2.87% |
1,575,000
+830,720
| +112% | +$27.7M |
|
16
Haemonetics
HAE
$3.85B
| $46.2M | 2.61% |
+1,150,000
| New | +$43.4M |
|
17
Encompass Health
EHC
$11B
| $41.3M | 2.33% |
1,257,659
-816,391
| -39% | -$26.5M |
|
18
Neurocrine Biosciences
NBIX
$18.7B
| $38.3M | 2.16% |
+988,900
| New | +$44.8M |
|
19
Merck
MRK
$321B
| $33.4M | 1.89% |
594,709
-243,691
| -29% | -$14.3M |
|
|
ALXN
20
DELISTED
Alexion Pharmaceuticals
ALXN
| $31.9M | 1.81% |
261,140
-388,860
| -60% | -$47.6M |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $27.8M | 1.57% |
625,000
-75,000
| -11% | -$2.64M |
|
22
CALL
Gilead Sciences
GILD
$163B
| $25.1M | 1.42% |
+350,000
| New | +$26M |
|
|
BCR
23
DELISTED
CR Bard Inc.
BCR
| $24.1M | 1.36% |
107,370
-92,630
| -46% | -$20.1M |
|
24
DexCom
DXCM
$28.8B
| $22.6M | 1.28% |
+1,514,600
| New | +$26.8M |
|
25
Collegium Pharmaceutical
COLL
$1.17B
| $22.2M | 1.25% |
1,426,300
+26,300
| +2% | +$437K |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2016 Portfolio in Review
As of Q4 2016, HealthCor Management held 53 positions worth $1.77B, up 7.8% from $1.64B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
HealthCor Management deployed $150M of net new capital in Q4 2016, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Intuitive Surgical: 1,575,000 shares worth $111M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 88% a quarter earlier, followed by Financials and Consumer Staples.
On the sell side, the largest reduction was Cigna, an estimated $74.6M trimmed.
- HealthCor Management's largest Q4 2016 buy was Intuitive Surgical: 1,575,000 shares worth $111M.
- HealthCor Management added most to Celgene Corp in Q4 2016, an estimated $151M increase.
- HealthCor Management's biggest Q4 2016 reduction was Cigna, cutting an estimated $74.6M.
- HealthCor Management fully exited Biogen in Q4 2016, selling an estimated $117M.
- HealthCor Management's ten largest holdings make up 57% of its $1.77B portfolio in Q4 2016.
- HealthCor Management opened 17 new positions and closed 14 in Q4 2016.
- HealthCor Management's portfolio value rose 7.8% quarter-over-quarter to $1.77B.
Based on HealthCor Management's 13F filing for Q4 2016, filed 14 Feb 2017.